Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart Failure - Full Text View

Sponsored by:	Novartis
Information provided by:	Novartis
ClinicalTrials.gov Identifier:	NCT00171106

Purpose

This study will test the effects of valsartan versus placebo on exercise tolerance in patients with symptoms of heart failure

Condition	Intervention	Phase
Diastolic Dysfunction, Symptomatic Heart Failure	Drug: valsartan	Phase IV

MedlinePlus related topics: Exercise and Physical Fitness Heart Failure

Drug Information available for: Valsartan

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Double-Blind, Randomised, Placebo-Controlled, Parallel Group Study to Determine the Effects of Valsartan on Exercise Time in Subjects With Symptomatic Diastolic Heart Failure

Further study details as provided by Novartis:

Primary Outcome Measures:

Secondary Outcome Measures:

Estimated Enrollment:	150
Study Start Date:	December 2002
Study Completion Date:	February 2008
Primary Completion Date:	August 2007 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	21 Years and older
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

Exclusion Criteria:

Uncontrolled hypertension
Asthma, COPD, or abnormal lung function
History of stroke, myocardial infarction, heart failure, chest pain, abnormal heart rhythm
Liver, kidney, or pancreas disease
Allergy to valsartan

Other protocol-defined exclusion criteria may apply

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00171106

Locations

Germany

Investigative Centers, Germany
Switzerland
Novartis Pharmaceuticals
Basel, Switzerland

Sponsors and Collaborators

Novartis

Investigators

Study Director:

Novartis Pharmaceuticals

More Information

Study ID Numbers:	CVAL489B2401
Study First Received:	September 10, 2005
Last Updated:	June 13, 2008
ClinicalTrials.gov Identifier:	NCT00171106
Health Authority:	United Kingdom: National Health Service

Keywords provided by Novartis:

diastolic dysfunction
heart failure
exercise tolerance
valsartan

Study placed in the following topic categories:

Heart Failure, Diastolic
Heart Failure
Heart Diseases
Valsartan

Additional relevant MeSH terms:

Therapeutic Uses
Cardiovascular Diseases
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009